122 related articles for article (PubMed ID: 19299238)
1. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
2. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
[TBL] [Abstract][Full Text] [Related]
3. The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors.
Galvano A; Gristina V; Scaturro D; Bazan Russo TD; Tomasello S; Vitagliani F; Carità F; La Mantia M; Fulfaro F; Bazan V; Mauro GL; Russo A
Front Endocrinol (Lausanne); 2023; 14():1297950. PubMed ID: 38075057
[TBL] [Abstract][Full Text] [Related]
4. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan.
Taguchi T; Matsushima H; Kodama S; Okubo N; Ito T; Ludwikowska M; Fukumoto S; Matsumoto T
Expert Opin Pharmacother; 2024 Feb; 25(3):325-334. PubMed ID: 38588537
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Gaillard S; Stearns V
Breast Cancer Res; 2011 Mar; 13(2):205. PubMed ID: 21457526
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
[TBL] [Abstract][Full Text] [Related]
7. [Effects of extended aromatase inhibitors in women with hormone-dependent breast cancer who have already received five years of adjuvant hormone therapy: A systematic review and meta-analysis].
Trenou KC; Mésidor M; Diorio C; Eslami A; Talbot D
Bull Cancer; 2024 Apr; 111(4):356-362. PubMed ID: 38453587
[TBL] [Abstract][Full Text] [Related]
8. Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial.
Zou X; Chen ZY; Yang YH; Qiao Y; He SJ; Li Q; Chen WL; Zhang XY; Li SY; Sha SY; Hu MH; Zhang XY; Yang MJ; Wang RP; Wu HG; Shi Y; Xue XH; Ji YJ
Integr Cancer Ther; 2023; 22():15347354231188679. PubMed ID: 37565358
[TBL] [Abstract][Full Text] [Related]
9. The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors :a systematic review and meta-analysis.
Lu G; Zheng J; Zhang L
Support Care Cancer; 2020 Apr; 28(4):1587-1596. PubMed ID: 31853701
[TBL] [Abstract][Full Text] [Related]
10. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.
Edwards BJ; Raisch DW; Shankaran V; McKoy JM; Gradishar W; Bunta AD; Samaras AT; Boyle SN; Bennett CL; West DP; Guise TA
Clin Cancer Res; 2011 Feb; 17(3):560-8. PubMed ID: 21288927
[TBL] [Abstract][Full Text] [Related]
11. Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study.
Bryce J; Bauer M; Hadji P
Cancer Manag Res; 2012; 4():105-11. PubMed ID: 22570564
[TBL] [Abstract][Full Text] [Related]
12. Increased Clinical Pain Locations and Pain Sensitivity in Women After Breast Cancer Surgery: Influence of Aromatase Inhibitor Therapy.
Zhu Y; Loggia ML; Edwards RR; Flowers KM; Muñoz-Vergara DW; Partridge AH; Schreiber KL
Clin J Pain; 2022 Dec; 38(12):721-729. PubMed ID: 36136765
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors-induced bone loss in early breast cancer.
Body JJ
Bonekey Rep; 2012; 1():201. PubMed ID: 24936287
[TBL] [Abstract][Full Text] [Related]
14. Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature.
Christensen Holz S
Curr Oncol Rep; 2023 Jul; 25(7):825-831. PubMed ID: 37052869
[TBL] [Abstract][Full Text] [Related]
15. Management of arthralgias associated with aromatase inhibitor therapy.
Thorne C
Curr Oncol; 2007 Dec; 14 Suppl 1(Suppl 1):S11-9. PubMed ID: 18087604
[TBL] [Abstract][Full Text] [Related]
16. Aromatase Inhibitor-Associated Distal Radioulnar Joint Instability and Tear of the Extensor Digiti Minimi: A Case Report.
Holt J; Salas M; Lee SW
Am J Phys Med Rehabil; 2024 Jul; 103(7):e86-e89. PubMed ID: 38466152
[TBL] [Abstract][Full Text] [Related]
17. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
Liang Y; Gersch CL; Lehman J; Henry NL; Smith KL; Rae JM; Stearns V; Hertz DL
Pharmacogenet Genomics; 2024 Jun; 34(4):126-129. PubMed ID: 38359166
[TBL] [Abstract][Full Text] [Related]
18. A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.
Robidoux A; Rich E; Bureau NJ; Mader S; Laperrière D; Bail M; Tremblay N; Patenaude M; Turgeon J
Curr Oncol; 2011 Dec; 18(6):285-94. PubMed ID: 22184490
[TBL] [Abstract][Full Text] [Related]
19. Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
Sehdev S; Martin G; Sideris L; Lam W; Brisson S
Curr Oncol; 2009 Jul; 16 Suppl 2(Suppl 2):S14-23. PubMed ID: 19672417
[TBL] [Abstract][Full Text] [Related]
20. Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.
Hadji P
Breast Care (Basel); 2010; 5(5):290-296. PubMed ID: 21779210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
